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a  b  s  t  r  a  c  t
Mathematical  modeling  of disease  transmission  has  provided  quantitative  predictions  for  health  pol-
icy,  facilitating  the  evaluation  of epidemiological  outcomes  and the  cost-effectiveness  of  interventions.
However,  typical  sensitivity  analyses  of  deterministic  dynamic  infectious  disease  models  focus  on  model
architecture  and  the  relative  importance  of parameters  but neglect  parameter  uncertainty  when  repor-
ting  model  predictions.  Consequently,  model  results  that  identify  point  estimates  of intervention  levels
necessary  to terminate  transmission  yield  limited  insight  into  the  probability  of  success.  We apply  prob-
abilistic  uncertainty  analysis  to  a dynamic  model  of  inﬂuenza  transmission  and  assess  global  uncertainty
in  outcome.  We  illustrate  that when  parameter  uncertainty  is  not  incorporated  into  outcome  estimates,
levels  of vaccination  and  treatment  predicted  to  prevent  an  inﬂuenza  epidemic  will  only  have  an  approx-
imately  50%  chance  of  terminating  transmission  and  that sensitivity  analysis  alone  is not sufﬁcientncertainty to  obtain  this  information.  We  demonstrate  that  accounting  for parameter  uncertainty  yields  proba-
bilities  of  epidemiological  outcomes  based  on  the degree  to  which  data  support  the  range  of  model
predictions.  Unlike  typical  sensitivity  analyses  of  dynamic  models  that  only  address  variation  in parame-
ters,  the probabilistic  uncertainty  analysis  described  here  enables  modelers  to convey  the  robustness
of  their  predictions  to policy  makers,  extending  the  power  of  epidemiological  modeling  to improve
013  T
public  health.
© 2
ntroduction
Epidemiological models can serve as powerful tools to predict
nd understand the dynamics of infectious diseases. These models
llow us to target control measures and use limited resources more
fﬁciently. However, the predictions of a model are highly depen-
ent on the quality of the data used for parameterization. Therefore,
t is crucial that proper care is given to the provenance and pre-
ision of data available, and that uncertainty in model outcomes
e addressed. Epidemiological models can be broadly classiﬁed as
eterministic or stochastic, where deterministic models have ﬁxed
arameter values and stochastic models have probabilistic values
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(Anderson and May, 1991; Keeling and Rohani, 2008; Vynnycky
and White, 2010). Although stochastic simulations of disease
transmission more often convey uncertainty by characterizing the
probability of an epidemiological outcome as part of an uncertainty
analysis (e.g. Fraser et al., 2009), deterministic models typically do
not. As a case in point, the study of inﬂuenza has been markedly
advanced by a number of insightful deterministic models (e.g. An
der Heiden et al., 2009; Chen and Liao, 2008; Crowe et al., 2011;
Flahault et al., 2006; Krumkamp et al., 2010; Medlock and Galvani,
2009; Mercer et al., 2011; Mylius et al., 2008; Nun˜o et al., 2007;
Roberts et al., 2007; Tracht et al., 2011; Tuite et al., 2010). However,
while sensitivity analysis is performed on these models and the rel-
ative importance of parameters’ contributions to uncertainty in the
model outcomes determined, global outcome uncertainty has not
been examined. Uncertainty analysis and its representation of the
total possible uncertainty in model outcomes would strengthen
policy makers’ conﬁdence in the interpretation of results and
Open access under the CC BY-NC-ND license.enhance their ability to act accordingly. Indeed, uncertainty
analysis has been previously applied to infectious disease models
without public health interventions (Blower and Dowlatabadi,
1994; Chowell et al., 2004; Coelho et al., 2008; Matser et al., 2009;
D license.
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amsuzzoha et al., 2013; Sanchez and Blower, 1997) and has been
ecommended by experts for many ﬁelds of mathematical mod-
ling, including medical decision making, as an optimal approach
o presenting model predictions (Briggs et al., 2012). In the case of
ynamic transmission modeling, however, authoritative best prac-
ices have not included uncertainty analyses (Pitman et al., 2012).
eneral modeling guidelines recommend the methodology used in
 probabilistic sensitivity analysis, in which both global parameter
ncertainty and output uncertainty are addressed, as the best
ractice method for uncertainty analysis (Briggs et al., 2012) but
hat ideal has not been extended to dynamic transmission models,
or which its implementation has been challenging (Pitman et al.,
012). Moreover, previous applications of uncertainty analysis
ethodology to dynamic models have not extended the technique
o the evaluation of public health interventions that are impor-
ant for reducing diseases transmission or avoiding epidemics
ltogether.
One challenge to the estimation of epidemiological param-
ters is the imprecision of the relevant data, stemming from
urdles to acquisition, privacy restrictions, and/or the need for
nalysis during outbreaks. Unfortunately, parameterizing a deter-
inistic epidemiological model with the best point estimates
ased on minimal data can convey a misleading degree of cer-
ainty to policy makers. Conversely, policy makers who are aware
hat models are parameterized with weakly supported point esti-
ates may  be overly dismissive of deterministic predictions that
ight yet have signiﬁcant validity. These issues can be addressed
y incorporating the uncertainty of parameters directly into an
nalysis by probabilistically re-sampling data or likely distri-
utions of parameters to calculate a distribution of predictive
utcomes given the model as part of a probabilistic uncertainty
nalysis (Blower and Dowlatabadi, 1994; Elderd et al., 2006;
elton and Davis, 2003; Marino et al., 2008; Sanchez and Blower,
997).
One of the most common modeling approaches for evaluat-
ng interventions in dynamic systems is the construction of a
ifferential equation model of a disease, such as the standard deter-
inistic Susceptible-Infected-Recovered (SIR) model (Anderson
nd May, 1991; Keeling and Rohani, 2008; Vynnycky and White,
010). From the differential equation model, a closed-form solu-
ion can be calculated for the basic reproductive number, R0, the
verage number of secondary infections that would follow upon
 primary infection in a naïve host population (Anderson and
ay, 1991; Keeling and Rohani, 2008; Van den Driessche and
atmough, 2002; Vynnycky and White, 2010). In a population
here there is pre-existing immunity due to either vaccination or
revious infection, the effective reproductive number, Re, is deﬁned
s the average number of secondary infections following a pri-
ary infection in a population that is not completely naïve, as
s true when vaccination or treatment is implemented (Keeling
nd Rohani, 2008; Vynnycky and White, 2010). Re is of particu-
ar interest in public health because interventions that bring its
alue below one are predicted to eradicate the disease (Keeling
nd Rohani, 2008; Vynnycky and White, 2010). Thus, the Re = 1
hreshold often serves as a target for designing effective inter-
ention policies (Keeling and Rohani, 2008; Vynnycky and White,
010).
While deterministic SIR models can provide valuable estimates
f the impact of interventions, they are often hampered by two
ritical limitations. First, the model often lacks realism and stands
s just one of several competing models that are compatible with
he same empirical evidence. This concern is typically addressed
y comparing model predictions to real-world data (Helton and
avis, 2002, 2003; Keeling and Rohani, 2008; Vynnycky and White,
010), but can also be addressed using Bayesian model averaging,
odel selection, and expert elicitation (Hoeting et al., 1999; Lloyd,ics 6 (2014) 37–45
2009;  Kass and Raftery, 1995; Saltelli et al., 2004). Second, the best
parameter estimates (needed for the closed-form solution of Re)
are often inexact. To address this concern, sensitivity analyses are
used to explore the relationship between model parameters and
outcomes. Speciﬁcally, one or more parameters are perturbed and
the corresponding effects on outcomes are examined (Marino et al.,
2008). The perturbation can be done either by evaluating the effect
of arbitrarily small changes in parameter values (e.g. ±1%, as in
Massad et al., 2009) or by evaluating the effects across a range
of values deﬁned by plausible probability density functions (e.g.
Amaku et al., 2003, 2009). However, because the values of other
parameters are held ﬁxed at best point estimates, these strate-
gies do not account for interaction effects in non-linear dynamic
models, and do not assess global uncertainty in parameters or
outcome.
A global probabilistic sensitivity analysis allows the contribu-
tion of each parameter to model outcomes to be investigated while
also taking into account the uncertainty of other model parameters
(Blower and Dowlatabadi, 1994; Marino et al., 2008; Sanchez and
Blower, 1997; Wu  et al., 2013). Uncertainty in parameter values
can be accounted for by sampling randomly from empirical data
or from probability density functions ﬁt to empirical data. Such
sampling techniques include bootstrapping, Monte Carlo sampling,
and Latin hypercube sampling (Blower and Dowlatabadi, 1994;
Hastings, 1970; Helton and Davis, 2002, 2003; Metropolis et al.,
1953; Marino et al., 2008; Sanchez and Blower, 1997). The model
output generated from parameter samples can then be analyzed
using linear (e.g. partial correlation coefﬁcients), monotonic (e.g.
partial rank correlation coefﬁcients) and non-monotonic statis-
tical tests (e.g. sensitivity index) to determine the contribution
of each parameter to the variation in output values (Blower and
Dowlatabadi, 1994; Helton and Davis, 2002, 2003; Marino et al.,
2008; Sanchez and Blower, 1997; Wu et al., 2013). The model
itself may  also be treated as an uncertain parameter and varied
in the sensitivity analysis to determine the effect that the choice
of model has on the output. This technique, known as Bayesian
model averaging, can be computationally infeasible (Hoeting et al.,
1999; Kass and Raftery, 1995; Saltelli et al., 2004). Even the most
thoroughly data-driven studies often only report the results of a
global sensitivity analysis in terms of a ranking of parameters’ rel-
ative contributions to outcome uncertainty, without reporting the
outcome uncertainty itself. Probabilistic uncertainty analysis pro-
vides additional utility, carrying data-driven parameter uncertainty
through to the model outcomes, yielding probabilistic distribu-
tions rather than single value estimates of possible outcome values
(Blower and Dowlatabadi, 1994; Elderd et al., 2006; Helton and
Davis, 2003; Marino et al., 2008; Sanchez and Blower, 1997). A
probabilistic outcome distribution serves as a gold standard for
conveying the robustness and uncertainty of model results to pol-
icy makers that has yet to be widely adopted by the epidemiological
modeling community.
Here,  we  illustrate methodology by which parameter uncer-
tainty can be incorporated into model predictions using an example
of inﬂuenza antiviral and vaccination intervention, comparing
model predictions that include uncertainty analysis to predic-
tions that only include sensitivity analysis in order to reveal the
importance of analyzing both parameter and output uncertainty in
deterministic modeling studies. Performing a probabilistic sensitiv-
ity analysis and extending parameter uncertainty into the model
predictions, we  assess uncertainty in outcome, a procedure that
allows researchers to provide public health ofﬁcials with funda-
mentally important information – especially for key threshold
considerations such as the probability of disease eradication at each
level of an intervention – so that decision makers may  precisely
weigh the cost of the intervention against the potential for and
extent of success.
J.A. Gilbert et al. / Epidem
Fig. 1. Diagram of compartmental model of inﬂuenza transmission. Compartments
correspond  to susceptible [S], latently infected [E], infectious [I], recovered [R], vac-
cinated [V], treated [T] and hospitalized [H] individuals.  corresponds to force of
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Snfection, 1/ to duration of incubation period,  to rate of hospitalization,  to rate
f recovery following hospitalization, and  to ﬂu mortality rate. The remaining
ates  are described in Table 1.
ethods
athematical model
We  implemented a compartmental model of inﬂuenza trans-
ission that divides individuals into susceptible (S), latent (E),
nfected (I), recovered (R), treated (T), vaccinated (V), and hospi-
alized (H) states (Fig. 1). Values for parameters relevant to the
alculation of Re, which included secondary attack rate , dura-
ion of infectiousness 1/ı, treatment efﬁcacy εT, vaccine efﬁcacy
V, contact rate c and probability of hospitalization from inﬂuenza
nfection pH, were obtained from literature on seasonal inﬂuenza
Table 1; Belshe et al., 1998; Cauchemez et al., 2004; Halloran et al.,
007; Longini et al., 1982; Mossong et al., 2008; Sullivan et al., 1993;
hompson et al., 2003, 2004). Susceptible individuals acquire infec-
ion following contact with an infectious individual (I or T) with a
orce of infection , given by  = ˇ((I/N) + (1 − εT)(T/N)), where  ˇ is
he product of the contact rate c and the probability of infection
iven contact with an infectious individual 1 − (1 − )ı,  is the sec-
ndary attack rate or the proportion of individuals who  will become
nfected upon contact with an infectious individual during the total
nfectious period, ı is one divided by the duration of infectiousness,
 is the total number of individuals in the population, and εT is the
fﬁcacy of antiviral treatment at reducing infectiousness. A propor-
ion 1 − εV of vaccinated individuals (V) become infected following
ontact with an infectious individual with a force of infection ,
here εV is the efﬁcacy of the vaccine at reducing susceptibility. A
roportion pT of individuals who become infected (E) are treated
ith antivirals, proceeding into the treated class (T) at a rate .
hese individuals (T) have a reduced ability to infect susceptible
ndividuals, based on the efﬁcacy of antivirals εT. The remaining
nfected individuals (1 − pT)E proceed to the infected class (I) at a
able 1
arameter descriptions, values, distributions, and sources.
Parameter Point estimate 
Infectious perioda 1/ı 3.8 days 
Secondary attack rate  0.147 
Contact rate c 13.4 contacts/day 
Vaccine efﬁcacy εV 0.95 
Antiviral treatment efﬁcacy εT 0.808 
Proportion of infected individuals hospitalized pH 0.005 
D, standard deviation.
a 1/recovery rate.
b Standard deviation = 0.4.
c All values greater than 0.
d Standard deviation = 0.037.
e From 1 − Beta(7,163)Beta(64,468)
f From 1 − Beta(4,176)Beta(22,168)
g From
[Beta(1441,14687)/(1441/16128)](167812/226545805)
Beta(120,694)ics 6 (2014) 37–45 39
rate  . Infected (I) and treated (T) individuals recover from infection
at a rate ı and proceed to the recovered class (R). Infected individ-
uals (I) are also hospitalized (H) at a rate , from which they recover
(R) at a rate , or die from infection at a rate . The ﬂow of individ-
uals from one compartment to another is described by the ordinary
differential equations:
dS
dt
=  −S,
dE
dt
=  S + (1 − εV )V − E,
dI
dt
= (1 − pT )E − (ı + )I,
dT
dt
=  pTE − ıT,
dR
dt
= ıI + ıT + H,
dV
dt
=  −(1 − εV )V,
dH
dt
= I − (  + )H.
Reproductive number
Our  outcome of interest was  the probability with which Re was
suppressed below one for a given set of parameter values. To facil-
itate direct evaluation of outcome under uncertainty based on our
model, we  derived an expression for Re using the next generation
matrix method (Van den Driessche and Watmough, 2002) from this
model:
Re =
(
1 − pT
ı +  +
pT
ı
(1 − εT )
)(
ˇS0
N
+  (1 − εV )
ˇV0
N
)
, (1)
where   = pHı/(1 − pH), S = S0, V = V0, and E = I = T = H = R = 0.
Uncertainty analysis
We  evaluated outcomes from Eq. (1), incorporating parameter
uncertainty, to assess whether different levels of treatment (pT) and
vaccination (V0/N) would effectively lower Re to below one, thus
achieving the termination of transmission. Treatment (pT) and vac-
cination (V0/N) are considered to be controllable variables that can
be changed based on the intervention approach, in contrast to the
Distribution Reference
Normalb Cauchemez et al. (2004)
Truncated normalc,d Longini et al. (1982)
Empirical Mossong et al. (2008)
Betae Belshe et al. (1998)
Betaf Halloran et al. (2007)
Betag Sullivan et al. (1993), Thompson et al. (2003, 2004)
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odel parameters that have known values and do not change with
ntervention. To compare with the typical approach, we ﬁrst cal-
ulated Re using the best point estimates – the mean of the data
r distribution from the literature – for the values of the parame-
ers, without incorporating parameter uncertainty (see Table 1 for
arameter values and distributions). We  then performed an uncer-
ainty analysis (Saltelli et al., 2008): for each parameter, we  sought
o use the most informative data available in the literature, in the
orm of data from an experiment or a distribution that had been ﬁt-
ed to such data. We  sampled from each parameter’s distribution to
erform the uncertainty analysis. The methods for estimating the
ncertainty distributions for secondary attack rate , duration of
nfectiousness 1/ı, vaccine efﬁcacy εV, treatment efﬁcacy εT, pro-
ortion of infected individuals hospitalized pH, and contact rate c
rom available data are detailed in the Appendix. The probability
hat Re was less than one was then calculated across the full range
f combinations of the variables pT and V0/N. We  performed this
alculation by computing Re for ﬁxed variables pT and V0/N while
andomly sampling the other parameters from their uncertainty
istributions. Repeating this process of Monte Carlo sampling for
he other parameters and calculating Re 10,000 times enabled us
o generate a distribution of all possible values for our outcome Re
or each pair of variables pT and V0/N. The probability that Re was
elow one for each pair of variables pT and V0/N was therefore equal
o the number of Re values less than one divided by 10,000.
We  assumed that the parameter distributions were independent
f each other because joint distribution data were not available. In
eality, it is unlikely that all model parameters are independent.
n general, correlation between parameters would be expected to
educe the overall uncertainty in outcome predictions. To assess
hether issues of parameter independence would signiﬁcantly
mpact our outcome, we repeated our analysis while imposing
omplete inverse correlation between the parameters  and ı.
hese parameters correspond to pathogen virulence and dura-
ion of infectiousness, which theory suggests may  be correlated
Galvani, 2003).
ensitivity analysisTo  assess the contribution of each parameter to the overall
ncertainty in Re, we performed one-way and global probabilis-
ic sensitivity analyses. For the one-way sensitivity analysis, we
Fig. 2. Probability (%) that Re is below one for different levels of vaccination and treics 6 (2014) 37–45
varied  each parameter individually across the 90% conﬁdence inter-
val of its uncertainty distribution and determined the minimum
and maximum Re value achieved at various combinations of vac-
cination and treatment coverages. The coverages were chosen to
correspond to potential plausible levels achievable in the United
States (Centers for Disease Control and Prevention, 2009). We  plot-
ted the results of the one-way sensitivity analysis in a series of
tornado diagrams, corresponding to the different combinations of
treatment and vaccination levels. For the global sensitivity analy-
sis, we  performed both partial rank correlation coefﬁcient (PRCC)
and sensitivity index calculation at different combinations of ﬁxed
treatment and vaccinations levels. Detailed methodology on PRCC
calculation can be found in Blower and Dowlatabadi (1994), as well
as Wu  et al. (2013). To calculate the sensitivity index for the param-
eters in Xi (i.e. c, ı, pH, εT, , and εV), while ﬁxing the proportion
of individuals treated and vaccinated, we evaluated the following
equation (Saltelli et al., 2008) for each parameter:
Si =
VXi (EX∼i (Re|Xi))
V(Re)
, (2)
where  VXi (EX∼i (Re|Xi)) is the variance of the expected value of model
output Re when holding Xi ﬁxed across all its possible values and
allowing the other parameters to vary, and V(Re) is the variance of
Re. This sensitivity index quantiﬁes the degree to which our out-
come Re is expected to vary when a given parameter is known
exactly. It ranges from zero to one, with higher values indicating
greater sensitivity of an outcome to the parameter uncertainty.
Results
Model  predictions without uncertainty
When point estimates of parameter values were used, our
compartmental model predicted that proportions of inﬂuenza vac-
cination above 0.54 or treatment above 0.64 would reduce Re below
one regardless of the value of the other proportion (Fig. 2). A com-
bination of lower vaccination and lower treatment levels were also
predicted to reduce Re below one (Fig. 2), indicating that vaccinating
less than 54% of susceptible individuals and treating less than 64%
of infected individuals could prevent an epidemic provided these
interventions are implemented at the same time.
atment (A) without and (B) with the incorporation of parameter uncertainty.
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odel predictions with uncertainty
Inclusion of parameter uncertainty demonstrated that higher
reatment and vaccination levels were required to reduce Re below
ne with a probability greater than 50% (Fig. 2). When interven-
ion was based exclusively on vaccination, only proportions of
accination above 0.69 reduced Re below one with a probabil-
ty above 90% (Fig. 2). Reducing Re below one with a probability
bove 99% requires a minimum of 0.76 vaccine coverage (Fig. 2).
hen intervention was based exclusively on treatment, even
igher levels of treatment were required to reduce Re below one
ith the same probability as that for vaccination. Proportions of
reatment above 0.87 could reduce Re below one with a proba-
ility above 90% (Fig. 2). No level of treatment was  alone able
o reduce Re below one with a probability above 99% (Fig. 2).
he levels of vaccination and treatment previously estimated to
chieve eradication (Re < 1) without uncertainty analysis are pre-
icted to only do so with probability 50% with uncertainty analysis.
hese ﬁndings indicate that, compared to the model’s predictions
ithout the inclusion of parameter uncertainty, increased levels
f intervention are required to reduce Re below one with a high
robability.
When the maximum level of treatment or vaccination achiev-
ble is known, the probability of the reduction of Re below one can
e depicted with a ﬁxed level of the known variable and varying
evels of the unknown variable (Fig. 3). For example, about three
ut of ten people choose to be vaccinated for inﬂuenza in a given
ear (Centers for Disease Control and Prevention, 2009). For this
ituation, the outcomes can be depicted with varying levels of
reatment and a ﬁxed proportion of vaccination of 0.3 (Fig. 3).
ith this level of vaccination, proportions of treatment above
.66 could reduce Re below one with a probability above 90%, and
roportions of treatment above 0.94 could reduce Re below one
ith a probability above 99%. Conversely, if it is already known that
here are only enough antivirals in a country’s stockpile to treat 3
ut of 10 infected people during an outbreak, policy makers can
e best served by information on the probability of eliminating an
pidemic of inﬂuenza when the proportion of infected individuals
ho are treated is 0.3 (Fig. 3). With this level of treatment, propor-ions of vaccination above 0.57 could reduce Re below one with a
robability above 90%, and proportions of vaccination above 0.66
ould reduce Re below one with a probability above 99%. These
esults provide a basis for decision-making regarding mitigating
ig. 3. Probability that Re is below one (A) for varying levels of treatment when proportion
s  0.3.ics 6 (2014) 37–45 41
an  epidemic that incorporates probability of successful eradication
given existing and potential levels of intervention.
Imposing an anticorrelation between parameters  and ı mod-
erately reduced the level of vaccination needed to reduce Re below
one relative to that depicted in Fig. 2. However, the breadth of
uncertainty around the effect of treatment remained the same. In
addition, the breadth of uncertainty around the effect of vaccina-
tion remained high as well as centered around the deterministic
prediction. Accordingly, correlation between parameters appears
not to impact our conclusion that a full uncertainty analysis reveals
key information for evaluating the predictions of epidemiological
models.
Sensitivity analysis
Our  sensitivity analysis to determine the sources of uncertainty
in our outcome Re demonstrated that we need more data (in order
of priority) on secondary attack rate , treatment efﬁcacy εT, vac-
cine efﬁcacy εV, contact rate c, duration of infectiousness 1/ı and
probability of hospitalization from inﬂuenza infection pH, respec-
tively, to provide greater predictive power to estimate Re (Fig. 4
and Tables 2 and 3). Secondary attack rate  and treatment efﬁ-
cacy εT have the greatest contributions to uncertainty in Re. The
one-way sensitivity analysis demonstrated that when  was  varied
across the 90% conﬁdence interval of its uncertainty distribution
and all other parameters are held ﬁxed, the greatest range in Re
was achieved, with a minimum value of 0.4 and maximum of 1.6,
depending on the level of vaccination and treatment implemented
(Fig. 4). The next widest ranges of Re values occurred when εT
and εV were varied across the 90% conﬁdence interval of their
uncertainty distributions (Fig. 4). The difference between the min-
imum and maximum Re values when varying εT or εV was greatest
when treatment or vaccination coverage, respectively, was highest
(Fig. 4).
The  global sensitivity analyses (PRCC and sensitivity index)
conﬁrmed that  and εT had the greatest inﬂuence on Re, even
when uncertainty in the other parameters was controlled for
(Tables 2 and 3). The PRCCs for  and εT were positive and negative,
respectively, greater than the PRCCs for the remaining parameters,
and statistically signiﬁcant, indicating that there is a strong mono-
tonic relationship between the parameters and Re (Table 2). Lower
values of Re were achieved, regardless of vaccination or treatment
coverage, when  was decreased or εT increased. Parameter εV had
 vaccinated is 0.3 and (B) for varying levels of vaccination when proportion treated
42 J.A. Gilbert et al. / Epidemics 6 (2014) 37–45
Fig. 4. One-way, local sensitivity analysis of parameter contributions to model outcome uncertainty at different combinations of vaccination and treatment levels. (A) 30%
treatment and 30% vaccination coverage, (B) 30% treatment and 35% vaccination coverage, (C) 30% treatment and 51% vaccination coverage, (D) 30% treatment and 60%
v atmen
( ation
5
t
t
a
c

Raccination coverage, (E) 37% treatment and 30% vaccination coverage, (F) 37% tre
H)  37% treatment and 60% vaccination coverage, (I) 50% treatment and 30% vaccin
1%  vaccination coverage, and (L) 50% treatment and 60% vaccination coverage.
he next highest absolute PRCC value and was inversely and mono-
onically correlated with Re, with εV becoming more inﬂuential
s vaccination coverage increased. Sensitivity index calculations
onﬁrmed that  and εT were the most inﬂuential parameters, with
 contributing to between 87.2% and 96.6% of the uncertainty in
e estimates and εT to between 2.4% and 10.1% (Table 3). Thet and 35% vaccination coverage, (G) 37% treatment and 51% vaccination coverage,
 coverage, (J) 50% treatment and 35% vaccination coverage, (K) 50% treatment and
remaining  parameters contributed to less than 1% of the
uncertainty in Re.The relative importance of parameters is partly determined by
the lack of data on these parameters, but is also in accord with
the important roles played by , εT, and εV in the calculation of
Re (Eq. (1)):  is raised to the power of ı and multiplied by the
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Table  2
PRCC  for each model parameter at different combinations of treatment and vaccination coverages. Higher absolute values indicate that a parameter contributes a greater
amount to the uncertainty in Re .
30% Vaccinated 35% Vaccinated 51% Vaccinated 60% Vaccinated
Parameter PRCC p-Value PRCC p-Value PRCC p-Value PRCC p-Value
30% treated Secondary attack rate  0.996 <0.001 0.996 <0.001 0.996 <0.001 0.995 <0.001
Antiviral  treatment efﬁcacy εT −0.862 <0.001 −0.860 <0.001 −0.845 <0.001 −0.826 <0.001
Vaccine  efﬁcacy εV −0.353 <0.001 −0.422 <0.001 −0.623 <0.001 −0.727 <0.001
Contact  rate c 0.354 <0.001 0.350 <0.001 0.328 <0.001 0.304 <0.001
1/(Duration  of infectious period) ı −0.098 <0.001 −0.097 <0.001 −0.091 <0.001 −0.085 <0.001
Proportion  of infected individuals hospitalized pH −0.029 0.003 −0.030 0.002 −0.033 0.001 −0.033 0.001
37% treated Secondary attack rate  0.994 <0.001 0.994 <0.001 0.994 <0.001 0.993 <0.001
Antiviral  treatment efﬁcacy εT −0.871 <0.001 −0.870 <0.001 −0.861 <0.001 −0.849 <0.001
Vaccine  efﬁcacy εV −0.286 <0.001 −0.346 <0.001 −0.551 <0.001 −0.661 <0.001
Contact  rate c 0.284 <0.001 0.282 <0.001 0.268 <0.001 0.254 <0.001
1/(Duration  of infectious period) ı −0.079 <0.001 −0.078 <0.001 −0.075 <0.001 −0.072 <0.001
Proportion  of infected individuals hospitalized pH −0.024 0.017 −0.025 0.013 −0.027 0.006 −0.029 <0.001
50% treated Secondary attack rate  0.988 <0.001 0.988 <0.001 0.987 <0.001 0.987 <0.001
Antiviral  treatment efﬁcacy εT −0.887 <0.001 −0.886 <0.001 −0.883 <0.001 −0.878 <0.001
Vaccine  efﬁcacy εV −0.204 <0.001 −0.250 <0.001 −0.425 <0.001 −0.540 <0.001
Contact  rate c 0.199 <0.001 0.198 <0.001 0.192 <0.001 0.185 <0.001
1/(Duration  of infectious period) ı −0.057 <0.001 −0.060 <0.001 −0.055 <0.001 −0.054 <0.001
Proportion  of infected individuals hospitalized pH −0.018 0.072 −0.019 0.064 −0.021 0.037 −0.023 0.023
Table 3
Sensitivity index (SI) for each model parameter at different combinations of treatment and vaccination coverages. Higher values indicate that a parameter contributes a
greater  amount to the uncertainty in Re .
30% Vaccinated 35% Vaccinated 51% Vaccinated 60% Vaccinated
Parameter SI SI SI SI
30% treated Secondary attack rate  0.966 0.966 0.961 0.955
Antiviral treatment efﬁcacy εT 0.025 0.025 0.025 0.024
Vaccine efﬁcacy εV 0.001 0.002 0.006 0.012
Contact rate c 0.001 0.001 0.001 0.001
1/(Duration of infectious period) ı  <0.001 <0.001 <0.001 <0.001
Proportion of infected individuals hospitalized pH <0.001 <0.001 <0.001 <0.001
37%  treated Secondary attack rate  0.946 0.945 0.941 0.935
Antiviral treatment efﬁcacy εT 0.043 0.043 0.043 0.042
Vaccine efﬁcacy εV 0.001 0.002 0.006 0.012
Contact rate c 0.001 0.001 0.001 0.001
1/(Duration of infectious period) ı  <0.001 <0.001 <0.001 <0.001
Proportion of infected individuals hospitalized pH <0.001 <0.001 <0.001 <0.001
50%  treated Secondary attack rate  0.881 0.881 0.877 0.872
Antiviral treatment efﬁcacy εT 0.101 0.100 0.100 0.099
Vaccine efﬁcacy εV 0.001 0.002 0.006 0.011
Contact rate c 0.001 0.001 0.001 0.001
<0.0
<0.0
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t1/(Duration of infectious period) ı 
Proportion of infected individuals hospitalized pH
roportion of individuals who are susceptible S0/N. Parameters εT
nd εV additionally serve as multipliers in Eq. (1).
iscussion
Here we demonstrated that incorporation of parameter uncer-
ainty into the analysis of deterministic models provides a key tool
or policy decisions regarding levels of public health interventions
eeded to halt an epidemic. These results hold true even for a
elatively well-investigated disease such as inﬂuenza. Without the
nclusion of parameter uncertainty, mathematical analysis often
ields a single threshold value corresponding to the level of an
ntervention that presumably leads to a successful outcome. We
ave shown that such a threshold value for an intervention suggests
n undue level of robustness for a model’s predictions regarding
he mitigation of a potential epidemic. In reality, the levels of
accination and treatment indicated by deterministic modeling
alt an outbreak only about half of the time. Procuring a more
alatable chance of success will take greater levels of intervention,
he amount of which depends critically on the data available on01 <0.001 <0.001 <0.001
01 <0.001 <0.001 <0.001
key  parameters. Quantifying the relationship between levels of
interventions and the probabilities of success requires uncertainty
analysis, and communicating this probabilistic understanding to
policy makers is of vital importance.
For instance, we  found that without the inclusion of parameter
uncertainty, our model predicted that levels of vaccination above
54% or treatment coverage above 64% could successfully control
a ﬂu epidemic. These results may  mislead a decision maker into
thinking that an inﬂuenza epidemic would deﬁnitely be avoided
if 54% of a population were vaccinated or 64% treated and the
subsequent development of public policy to promote this cover-
age level. However, we  saw that when parameter uncertainty was
incorporated and uncertainty in the model outcome was analyzed,
predicted intervention levels would only successfully control an
epidemic 50% of the time; much higher coverage levels – closer
to 70% for vaccination and 90% for treatment – were needed to
be 90% certain these interventions would successfully control an
epidemic. The same principle holds true for stochastic epidemi-
ological models that do not perform uncertainty analysis, since
often these models alone do not capture the full plausible range
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f parameter values and therefore do not convey the total uncer-
ainty in model outcomes. Quantiﬁcation of uncertainty provides
olicy makers the opportunity to weigh deployment of resources
gainst risks in choosing the appropriate combination of vaccina-
ion and treatment coverage levels at the beginning of or potentially
efore the start of an epidemic in order to successfully mitigate the
umber of infections and deaths.
Sources of outcome uncertainty can additionally be identiﬁed by
eterministic sensitivity analysis to indicate where to direct further
mpirical research efforts. Typically, in epidemiological modeling
f disease transmission, deterministic sensitivity analyses are per-
ormed by taking the derivatives of outcome variables at best point
stimates or by analyses of slight perturbations without explicit
egard to sampling error. This approach is not ideal when the
arameters are not precisely known or when the model is non-
inear, as the analysis is only informative at the point estimates from
hich it is computed. The one-way sensitivity analysis performed
n our inﬂuenza model is an example of a deterministic, local sensi-
ivity analysis. While the one-way sensitivity analysis ranked each
arameter in order of importance, as well as gave ranges of possible
e values, it did not control for uncertainty in the other parame-
ers, account for interactions between parameters, or quantify the
robability that Re would be less than one. A global sensitivity anal-
sis that takes the uncertainty of all parameters into account is
ore appropriate for epidemiological models of disease transmis-
ion. The global sensitivity analyses performed on our inﬂuenza
odel also ranked the parameters in order of importance, but con-
rolled for global parameter uncertainty. They demonstrated that
econdary attack rate most inﬂuenced our outcome Re. Accord-
ngly, to model inﬂuenza transmission more precisely, additional
esearch studies should focus on precise estimation of the sec-
ndary attack rate. However, PRCC and sensitivity index calculation
id not indicate the potential ranges of Re that were achieved at the
ifferent vaccination and treatment levels, nor did it give an indi-
ation regarding how likely different intervention levels were to
ucceed (i.e. reduce Re below one). The information regarding the
otal uncertainty in Re estimates for each intervention level and
he probability of intervention success was only gained through
he probabilistic uncertainty analysis.
While we used a relatively basic model of inﬂuenza to illus-
rate our methodology, the approach that we advocate can be
pplied more generally by incorporating additional details into
he model structure. For example, age structure would be highly
ppropriate to include when investigating potential vaccination
olicies for inﬂuenza. Moreover, other disease models might not
equire a recovered compartment because recovery is either not
ossible (e.g. HIV/AIDS) or immunity is not acquired (e.g. gon-
rrhea; Vynnycky and White, 2010). The model structure should
eﬂect the important disease characteristics. However, regardless
f model complexity, parameter uncertainty will always exist and
ill always impact model predictions. Therefore, an uncertainty
nalysis is necessary for all types of dynamic transmission models.
Because it is not always clear what the model structure for a
isease should be, uncertainty in model speciﬁcation also exists.
ncertainty in model speciﬁcation, if incorporated into an analysis
Hoeting et al., 1999), would be expected to further increase the
ncertainty of model predictions. In our model, for example, we
ould have instead allowed infected individuals to be infectious
or a period of time before being treated. Under this alternate
cenario, the outcome Re would have to be calculated by a different
quation, potentially leading to a different uncertainty in outcome.
ur sensitivity analysis might also have identiﬁed a different
arameter as most inﬂuential of our outcome Re. As with many
ther studies, however, our ultimate choice of model structure was
ictated in part by the data available for parameter values. While
his more complex model would be a more realistic portrayal ofics 6 (2014) 37–45
the natural history of inﬂuenza, we  could not ﬁnd any dataset
to create an appropriate distribution for the amount of time an
individual was  infected before treatment and therefore we did
not incorporate the additional complexity to predict proportions
of vaccination and treatment required to prevent or forestall an
epidemic. Our study is not intended to directly inﬂuence policy but
rather to demonstrate the importance of uncertainty analysis. Fur-
thermore, because we  focus on a single strain of inﬂuenza, we have
structured our analysis to address uncertainty associated with the
statistical measurement of parameters in research studies. Addi-
tional uncertainty exists in the biological variation between strains
of inﬂuenza, which is important when considering more than one
season of inﬂuenza transmission. For diseases other than inﬂuenza,
variation in parameter estimates between studies conducted at
different times or in different populations may also need to be
addressed. Ideally, a single study that is viewed as the best dataset
can be selected for parameterization of a model. When it is not
clear which data source is most appropriate to use, study variation
can be addressed with meta-analysis, sampling from multiple
distributions for a parameter, or imposing a uniform distribution
on the minimum and maximum values found in literature.
In  summary, sensitivity analysis of our inﬂuenza model identi-
ﬁed the secondary attack rate as the parameter that most inﬂuenced
our outcome Re. Accordingly, to model inﬂuenza transmission more
precisely, additional research studies should focus on estimating
precise values of the secondary attack rate. Moreover, because pol-
icy makers are interested in the predicted impact of different types
and levels of interventions on an epidemic, estimated effects of an
intervention should be presented to policy makers along with the
degree of credibility that these effects will occur in light of uncer-
tainty in the model parameters. Thereby, policy makers can make
a well-informed decision with an understanding of the probability
of success or failure based on the decision taken. Our study demon-
strates that this uncertainty can be incorporated into analyses
seamlessly by re-sampling from distributions of likely parameter
values, calculating the outcome of interest, and determining the
probability that the outcome is achieved, as we  illustrated here for
a model of inﬂuenza vaccination and treatment.
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